|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM34604670X |
| 003 |
DE-627 |
| 005 |
20231226030508.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231226s2022 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2022.109109
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1153.xml
|
| 035 |
|
|
|a (DE-627)NLM34604670X
|
| 035 |
|
|
|a (NLM)36087683
|
| 035 |
|
|
|a (PII)S1521-6616(22)00190-5
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Yaigoub, Hasnaa
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Bidirectional crosstalk between dysbiotic gut microbiota and systemic lupus erythematosus
|b What is new in therapeutic approaches?
|
| 264 |
|
1 |
|c 2022
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 12.10.2022
|
| 500 |
|
|
|a Date Revised 11.11.2022
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a Systemic lupus erythematosus is an autoimmune disease characterized by chronic inflammation and multiple organs damage. Its pathogenesis is complex and involves multiple factors including gut microbiota. Accumulating evidence indicates the interaction of microbial communities with the host immune system to maintain a state of homeostasis. Imbalances within the gut microbial composition and function may contribute to the development of many autoimmune diseases including SLE. In this review, we aim to highlight the dysregulation of commensal bacteria and their metabolites in the gastrointestinal tract and the resulting autoimmune responses in lupus and to decrypt the cross-link between the altered gut microbiota and the immune system in the SLE condition. We also provide new insights into targeting gut microbiota as a promising therapeutic approach to treat and manage SLE
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Review
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
4 |
|a Dysbiosis
|
| 650 |
|
4 |
|a Gut microbiota
|
| 650 |
|
4 |
|a Immune system
|
| 650 |
|
4 |
|a Metabolites
|
| 650 |
|
4 |
|a SLE treatment
|
| 650 |
|
4 |
|a Systemic lupus erythematosus
|
| 700 |
1 |
|
|a Fath, Nada
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Tirichen, Hasna
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Wu, Changxin
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Li, Rongshan
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Li, Yafeng
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 244(2022) vom: 28. Nov., Seite 109109
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:244
|g year:2022
|g day:28
|g month:11
|g pages:109109
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2022.109109
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 244
|j 2022
|b 28
|c 11
|h 109109
|